AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

By Hao Liu • Monday, June 22 10:52 • Permanent Link

AbbVie said it will buy Apogee Therapeutics for $135.11 a share in cash, valuing the biotech at about $10.9 billion.

The deal gives AbbVie a pipeline of clinical-stage inflammatory and immunology assets, led by zumilokibart, or APG777, a late-stage monoclonal antibody targeting IL-13 in atopic dermatitis. AbbVie also gets APG273, a combination program in asthma that pairs zumilokibart with APG333, an anti-TSLP antibody.

Apogee’s shares will be acquired at the same $135.11 per share price across all outstanding stock. The boards of both companies approved the transaction unanimously. AbbVie said the deal is expected to close in the third quarter of 2026.

The announcement comes with a data set AbbVie is clearly paying up for. In Apogee’s phase 2 study, about two-thirds of patients on treatment achieved significant skin clearance at 16 weeks, while the company said longer-term data supported maintenance dosing as infrequently as quarterly or twice a year. For APG333, phase 1 data showed suppression of relevant type 2 inflammatory markers for up to six months after dosing.

AbbVie said the transaction is expected to add to earnings beginning in 2032. As a result of these announcements, the company's shares have moved 4.79% on the market, and are now trading at a price of $226.8625. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.